查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715645

鼻腔药物和疫苗传输市场（按药物类型、剂型、设备类型、剂量、应用和最终用户划分）—2025 年至 2030 年全球预测

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年鼻腔内药物和疫苗输送市场价值为 469.8 亿美元，预计 2024 年将增长至 495.9 亿美元，复合年增长率为 5.88%，预计到 2030 年将达到 701.2 亿美元。

主要市场统计数据
基准年2023年 469.8亿美元
预计2024年 495.9亿美元
预测年份 2030 701.2亿美元
复合年增长率（%） 5.88%

鼻腔给药和疫苗输送是製药领域的重要进步，为传统给药途径提供了一种有效、非侵入性的替代方法。本介绍深入探讨了一个快速发展的市场，其特点是创新研究、技术突破和监管支持不断增加。随着研究人员、製造商和医疗保健专业人员不断探索优化治疗结果和提高患者依从性的方法，鼻腔给药因其吸收迅速、给药方便以及可直接进入全身和局部治疗途径的潜力而成为领先者。

这一领域的发展受到令人信服的临床数据和以患者为中心的研究的推动，这些研究表明，鼻内给药不仅可以增强吸收，还可以绕过主要的代谢障碍。因此，人们越来越重视在药物和疫苗方面利用这种方法。这份全面的概述探讨了当前市场动态的细微差别、产品设计和交付的技术创新以及重塑鼻内治疗格局的战略因素。随着此类输送系统的开发和应用势头强劲，它们有望彻底改变治疗几个主要治疗领域的药理学方法，包括疼痛、荷尔蒙失调、感染疾病和神经系统疾病。

随着市场认识到简化给药机制的重要性，鼻腔给药途径的采用正引起多方相关人员的兴趣。广泛的分析表明，其多面性正在导致对配方研究、设备创新和临床试验的大量投资。提供安全、有效和用户友好的药物输送选择的紧迫性仍然是正在进行的研究的重点，本报告力求清晰、准确地捕捉此类突破的本质。

重塑鼻腔给药​​格局的变革

近年来，发生了一些变革，重新定义了鼻内药物和疫苗传递的模式。随着研究的加速和革命性技术整合的出现，该行业正在经历模式转移，引起了全球相关人员的关注。政府关注度的提高和支持性监管政策为加速药品核准和创新试验设计铺平了道路。

从微流体喷雾器到精密设计的滴管，最尖端科技的引入凸显了鼻内给药系统成功发展的趋势。製造商正在大力投资产品开发工作，以确保优化的配方与尖端的输送装置相匹配，从而确保最大的治疗效果，同时最大限度地减少副作用。配方科学和设备技术交叉领域的专注努力带来了显着提高药物生物生物有效性的创新。此外，随着急性和预防性医疗干预中对快速起效的要求变得越来越重要，这些新型给药系统的功效正在临床界和患者群体的认可和接受。

随着我们对鼻腔生理学及其作为中枢神经系统输送通道的潜力的理解不断加深，产业领导者不仅投资于研发，而且还积极寻求策略联盟。这些伙伴关係正在加快创新步伐，创造一个可以在创纪录的时间内测试和改进新药和疫苗候选物的环境。这种转变由下一代鼻内製剂的强大管道进一步证明，这些製剂有望提高患者的依从性、改善安全性并扩大多种健康状况的治疗用途。简而言之，这些动态转变正在重新定义市场预期，并为整个产业建立强大的、面向未来的基础。

阐明市场结构的关键细分洞察

对鼻腔给药市场进行详细细分，可以发现其复杂的层次，这些层次对其整体广度和深度做出了重大贡献，说明了该行业的复杂性和动态性。基于药物类型的市场分析深入研究了止痛药、抗组织胺药物、类固醇、疫苗等应用。在此框架内，进一步检视止痛药以区分非鸦片类药物和鸦片类药物，并将疫苗明确分为灭活疫苗、减毒活病毒疫苗和基于 mRNA 的疫苗。这种详细的细分强调了多样化配方策略的必要性，并强调了不同治疗背景下不断变化的需求。

除此之外，市场还根据配方类型进行细分，重点关注凝胶、液体和粉末配方。这种分类反映了鼻腔製剂的物理特性和稳定性要求的多样性，最终影响製造过程和患者的可用性。同时，调查设备的类型也很重要，我们的分析重点是雾化器、滴鼻器和鼻喷雾等设备。每个设备在确保正确的剂量达到预期目标、最大限度地提高治疗效果和最大限度地减少药物输送的变化方面发挥关键作用。

此外，基于剂量的细分突出了多剂量产品和单位剂量产品之间的二分法。这种细分方面揭示了确保剂量精确度和优化不同临床场景的传输机制所需的操作挑战和技术创新。此外，按应用细分市场可以揭示广泛的治疗领域，包括过敏治疗、荷尔蒙替代、神经系统疾病、疼痛管理、精神疾病和药物传输治疗。对这些不同应用的认识突显瞭如何客製化鼻内给药以满足特定的临床需求。

此外，基于最终用户属性的细分包括居家医疗、医院/诊所和研究/学术机构等设置。这方面体现了以患者为中心的开发和研发的重视，并强调了鼻内给药的广泛效用。这些市场细分洞察揭示了一个多层次的市场，每个细分市场都对整体成长轨迹做出了独特的贡献，突显了专业化的机会和成熟的创新领域。对于希望有效指导研发投资和策略规划的相关人员来说，了解这些细微的差别至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 感染疾病的流行和对注射器相关感染的日益担忧正在推动鼻内给药系统的发展。
      • 自行用药和非侵入性给药途径的日益普及
      • 扩大专注于经鼻吸入型疫苗创新的研发活动
    • 限制因素
      • 替代药物传递方法的可用性和产品召回的潜在风险
    • 机会
      • 鼻内给药系统的进展
      • 大力投资鼻腔给药及疫苗输送创新研发
    • 任务
      • 与鼻腔内给药相关的潜在不良反应和副作用
  • 市场区隔分析
    • 药物类型：非鸦片类止痛药用于治疗慢性疼痛和长期使用的情况正在增加，因为它们成瘾和副作用的风险较低。
    • 配方类型：鼻腔药物和疫苗传递的创新解决方案和新兴应用
    • 设备类型：急救护理的准确性和有效性推动了对雾化器的需求
    • 剂量：由于成本效益和材料效率，多剂量形式越来越受到大规模疫苗接种计画和慢性治疗通讯协定的青睐。
    • 应用：在治疗过敏症时，越来越多人选择透过鼻腔给药和疫苗给药来注射皮质类固醇和抗组织胺药
    • 最终用户：便利性和隐私性的提高将推动居家照护环境中更多地采用鼻腔给药和疫苗给药
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 鼻腔给药及疫苗给药市场（依药物类型）

  • 止痛药
    • 非阿片类药物
    • 阿片类药物
  • 抗组织胺药
  • 类固醇
  • 疫苗
    • 灭活疫苗
    • 减毒活疫苗
    • 基于mRNA的疫苗

7. 鼻腔给药及疫苗递送市场（按剂型）

  • 凝胶配方
  • 液体製剂
  • 粉末製剂

8. 鼻腔给药及疫苗输送市场（依设备类型）

  • 雾化器
  • 滴鼻器
  • 鼻喷剂

9. 鼻腔给药和疫苗给药市场（按剂量）

  • 多剂量
  • 单位剂量

第十章 鼻腔给药与疫苗输送市场（依应用）

  • 过敏治疗
  • 荷尔蒙补充疗法
  • 神经系统疾病
  • 疼痛管理
  • 精神疾病
  • 治疗药物输送

第 11 章。鼻腔药物和疫苗传输市场（按最终用户划分）

  • 居家护理
  • 医院和诊所
  • 研究和学术机构

12.美洲鼻腔药物和疫苗传输市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区鼻腔药物和疫苗传输市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲鼻腔药物和疫苗传输市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery LP
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi SA
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market was valued at USD 46.98 billion in 2023 and is projected to grow to USD 49.59 billion in 2024, with a CAGR of 5.88%, reaching USD 70.12 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 46.98 billion
Estimated Year [2024] USD 49.59 billion
Forecast Year [2030] USD 70.12 billion
CAGR (%) 5.88%

Intranasal drug and vaccine delivery represents a significant advancement in the field of pharmaceuticals, offering an effective and non-invasive alternative to traditional routes of administration. This introduction sets the stage for an in-depth exploration of a rapidly evolving market characterized by innovative research, technological breakthroughs, and increasing regulatory support. As researchers, manufacturers, and healthcare professionals continually seek methods to optimize therapeutic outcomes and enhance patient compliance, intranasal delivery is emerging as a front-runner due to its potential for rapid absorption, ease of administration, and direct access to both systemic and localized treatment pathways.

The evolution of this niche sector has been driven by compelling clinical data and patient-centric studies, revealing that the nasal route not only accelerates absorption but also bypasses major metabolic barriers. Consequently, there is a growing emphasis on leveraging this method for both drugs and vaccines. This comprehensive overview will explore the nuances of the current market dynamics, the technological innovations in product design and delivery, and the strategic factors that are reshaping the landscape of intranasal therapy. As the development and application of these delivery systems gain momentum, they promise to transform the pharmacological approach to managing several major therapeutic areas, including pain, hormonal deficits, infectious diseases, and neurological disorders.

As the market acknowledges the importance of streamlined delivery mechanisms, the adoption of intranasal routes is drawing interest from a diverse spectrum of stakeholders. Insights drawn from extensive analysis demonstrate that the multifaceted nature has led to significant investments in formulation research, device innovations, and clinical trials. The urgency to provide safe, efficient, and user-friendly medication delivery options remains at the forefront of ongoing research, and this report endeavors to capture the essence of such breakthroughs with clarity and precision.

Transformative Shifts Reshaping the Intranasal Delivery Landscape

Over recent years, transformative shifts have redefined the framework within which intranasal drug and vaccine delivery operates. Marked by accelerated research and revolutionary technological integration, the industry is experiencing a paradigm shift that has captured the attention of global stakeholders. Increased governmental focus and supportive regulatory policies have paved the way for expedited drug approvals and innovative trial designs, thereby allowing novel products to reach the market faster than ever before.

The infusion of cutting-edge technologies, ranging from microfluidic atomizers to precision-engineered droppers, highlights the progressive trends that underpin the success of intranasal delivery systems. Manufacturers are investing substantially in product development efforts to ensure that optimized formulations are matched with state-of-the-art delivery devices, ensuring maximum therapeutic efficacy while minimizing adverse effects. This concerted focus on marrying formulation science with device technology has led to innovations that significantly improve drug bioavailability. Moreover, as the demand for rapid onset of action becomes increasingly critical in emergency treatments and preventive healthcare interventions, the efficacy of these novel delivery systems is being recognized and embraced by both the clinical community and patient populations.

Catalyzed by a growing understanding of nasal physiology and its potential as a gateway to central nervous system delivery, industry leaders are not only investing in research and development but are also actively engaging in strategic collaborations. Such partnerships are accelerating the pace of innovation and fostering an environment where novel drug and vaccine candidates can be tested and refined in record time. The transformation is further evidenced by the strong pipeline of next-generation intranasal products that promise enhanced patient compliance, improved safety profiles, and expanded therapeutic applications across numerous health conditions. In essence, these dynamic shifts are redefining market expectations and establishing a robust, future-oriented foundation for the entire industry.

Critical Segmentation Insights Illuminating Market Structure

A meticulous segmentation of the intranasal delivery market reveals intricate layers that contribute significantly to its overall breadth and depth, illustrating the complexity and dynamic nature of the field. Market analysis based on drug type delves into applications ranging from analgesics, antihistamines, steroids, and vaccines. Within this framework, analgesics are further scrutinized to differentiate between non-opioids and opioids, while vaccines are distinctly categorized into inactivated vaccines, live attenuated vaccines, and mRNA-based vaccines. This detailed segmentation underscores the need for varied formulation strategies and underscores the evolving requirements across different therapeutic contexts.

In parallel, the market is also segmented based on formulation type, where the focus is on gel, liquid, and powder formulations. This classification reflects the diversity in the physical characteristics and stability requirements of intranasal formulations, ultimately influencing both manufacturing processes and patient usability. Concurrently, the investigation into device type is crucial, with the analysis highlighting instruments such as atomizers, nasal droppers, and nasal sprays. Each device plays a critical role in ensuring that the right dose reaches its intended target, thereby maximizing therapeutic benefits and minimizing variability in drug delivery.

Additionally, segmentation based on dosage focuses on the dichotomy between multi-dose and unit-dose products. This aspect of segmentation sheds light on the operational challenges and technological innovations required to ensure accuracy in dosing and to optimize the delivery mechanism for various clinical scenarios. Furthermore, when the market is segmented by application, the insights extend to a wide array of therapeutic areas including allergy treatment, hormone replacement, neurological conditions, pain management, psychiatric disorders, and therapeutic drug delivery. The recognition of these diversified applications accentuates how intranasal delivery is being tailored to meet specialized clinical needs.

Moreover, segmentation based on end-user demographics includes settings such as homecare, hospitals and clinics, and research and academic institutions. This aspect signals the dual emphasis on both patient-centric and research-focused developments, emphasizing the broad utility of intranasal administration. Together, these segmentation insights reveal a layered market where each segment contributes uniquely to the overall growth trajectory, highlighting both opportunities for specialization and areas ripe for innovation. Understanding these nuanced segments is imperative for stakeholders looking to target their R&D investments and strategic planning effectively.

Based on Drug Type, market is studied across Analgesics, Antihistamines, Steroids, and Vaccines. The Analgesics is further studied across Non-opioids and Opioids. The Vaccines is further studied across Inactivated Vaccines, Live Attenuated Vaccines, and mRNA-based Vaccine.

Based on Formulation Type, market is studied across Gel Formulations, Liquid Formulations, and Powder Formulations.

Based on Device Type, market is studied across Atomizer, Nasal Dropper, and Nasal Spray.

Based on Dosage, market is studied across Multi-dose and Unit-dose.

Based on Application, market is studied across Allergy Treatment, Hormone Replacement, Neurological Conditions, Pain Management, Psychiatric Disorders, and Therapeutic Drug Delivery.

Based on End-User, market is studied across Homecare, Hospitals & Clinics, and Research & Academic Institution.

Detailed Regional Perspectives on Intranasal Delivery Innovations

A regional analysis of the intranasal drug and vaccine delivery market sheds light on diverse geopolitical trends and regional dynamics that are driving growth and innovation across the globe. In the Americas, robust healthcare infrastructure, substantial government funding, and a high rate of technology adoption foster an environment where novel intranasal products are swiftly integrated within existing clinical frameworks. These factors, combined with aggressive investments in research and development, have positioned the region as a leading market for next-generation therapies.

The Europe, Middle East & Africa region presents a contrasting yet equally compelling landscape. The region benefits from mature regulatory systems and an increasing emphasis on personalized healthcare solutions. Government initiatives and collaborative ventures among research institutions and private players are bolstering the development of advanced intranasal delivery systems. This convergence of resources and expertise underlines the region's commitment to addressing complex therapeutic challenges. Although regulatory environments may vary, the collective focus on innovation is driving a notable shift towards products that cater to both acute and chronic medical needs.

Turning attention to the Asia-Pacific region, the market dynamics are primarily characterized by rapid urbanization, rising healthcare awareness, and expanding consumer access to modern medical technologies. Emerging economies in this region are witnessing significant improvements in healthcare delivery systems, facilitated by government reforms and increased investments in R&D infrastructure. The potential to integrate intranasal delivery into large-scale public health initiatives, particularly in the context of vaccination programs, is further accelerating market penetration. This broad regional disparity in economic growth, healthcare policies, and technology adoption ultimately illustrates the varied and rich tapestry of regional market behaviors, each contributing uniquely to the upward growth trajectory of intranasal delivery innovations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-Depth Insights into Leading Companies and Competitive Positioning

A detailed competitive analysis of the intranasal drug and vaccine delivery market underscores the significant presence of several key industry players whose innovations and strategic initiatives are instrumental in shaping the future of the therapeutic landscape. Renowned entities such as Altimmune, Inc. and AptarGroup, Inc. are at the forefront of pioneering new formulations and delivery technologies. Major pharmaceutical organizations like AstraZeneca PLC, Bausch Health Companies Inc., and Bayer AG have consistently invested in research to optimize product performance and enhance patient outcomes. Likewise, companies with comprehensive portfolios, such as Becton, Dickinson, and Company, along with Bharat Biotech Ltd. and Boehringer Ingelheim International GmbH, are driving multifaceted initiatives that marry clinical efficacy with technological innovation.

Other prominent participants such as Catalent, Inc and DCA Design International Limited have been central in advancing device engineering to support the accuracy and consistency of intranasal delivery. In this competitive arena, Emergent BioSolutions Inc. and GlaxoSmithKline PLC have leveraged their extensive expertise in vaccine development to explore the untapped potential of the nasal route for immunization strategies. Companies such as Hovione Limited and Impel Pharmaceuticals LLC. are also generating considerable interest with their focus on formulating stable and efficient intranasal products. Meanwhile, Indivior PLC and Intersect ENT by Medtronic plc continue to capitalize on their technological capabilities to push the boundaries of therapeutic administration.

In parallel, players like Intertek Group PLC and Johnson & Johnson Services, Inc. are ensuring that quality assurance and regulatory compliance are given utmost priority, a critical factor in achieving market success. Kindeva Drug Delivery L.P. and Merck & Co., Inc. further cement their market stance by actively pursuing research initiatives that address unmet clinical needs through innovative product designs. The strategic imperatives of Neurelis, Inc. and Novartis AG have positioned these companies as pivotal contributors to the development of next-generation intranasal solutions. Other influential names including OptiNose, Inc., Pfizer Inc., Recipharm AB, Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd. complete this rigorous competitive landscape, each playing a significant role in driving both incremental and breakthrough advancements.

This competitive mosaic illustrates not only the depth of research and development efforts but also the collaborative spirit that has emerged across the industry. The convergence of varied expertise has accelerated the pace of innovation and established a robust foundation for ongoing product development, ensuring that the market remains both dynamic and responsive to emerging therapeutic needs.

The report delves into recent significant developments in the Intranasal Drug & Vaccine Delivery Market, highlighting leading vendors and their innovative profiles. These include Altimmune, Inc., AptarGroup, Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Becton, Dickinson, and Company, Bharat Biotech Ltd., Boehringer Ingelheim International GmbH., Catalent, Inc, DCA Design International Limited, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Hovione Limited, Impel Pharmaceuticals LLC., Indivior PLC, Intersect ENT by Medtronic plc, Intertek Group PLC, Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Merck & Co., Inc., Neurelis, Inc., Novartis AG, OptiNose, Inc., Pfizer Inc., Recipharm AB., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd.. Strategic, Actionable Recommendations for Market Leaders

In light of the current market trends and the deep segmentation insights gathered, industry leaders are provided with a suite of actionable recommendations that can be strategically deployed to optimize their competitive positioning. The first step involves a continued commitment to research and development, where investment in advanced formulation science and device technology remains paramount. Leaders should steer their innovation strategies toward integrative approaches that comprehensively address the full spectrum of patient needs while also streamlining production procedures.

Leveraging strategic partnerships and cross-industry collaborations can further enhance product pipelines and expedite market entry. Building robust networks with research institutions, regulatory bodies, and technology providers can lead to the early adoption of best practices, ensuring that new products are both effective and compliant with evolving standards. This collaborative approach not only mitigates risks associated with regulatory uncertainties but also acutely positions organizations to capitalize on emerging opportunities in niche therapeutic areas.

Emerging trends indicate that a focus on patient-centric product design is vital. Industry leaders are encouraged to invest in technologies and clinical research that provide granular insights into patient behaviors and treatment outcomes. Such investments can streamline the development of formulations that either target or effectively manage specific dosing requirements, thereby ensuring that the therapeutic efficacy is maximized. Additionally, optimizing the spectrum of device types-ranging from atomizers to nasal droppers and sprays-should now be considered a critical focus area. This refinement in the delivery mechanism can lead to significant improvements in patient adherence and overall drug performance.

Moreover, companies should undertake targeted market intelligence initiatives to monitor region-specific trends and competitive movements meticulously. Establishing agile research frameworks that are receptive to dynamic regulatory changes and are capable of quickly adapting to new market demands will be crucial for maintaining a competitive edge. Reinforcing investment in digital technologies to harness big data and predictive analytics can further refine market strategies and shape future investment pathways.

To encapsulate, it is essential for market leaders to adopt an integrated approach that leverages scientific innovation, strategic partnerships, and patient-centric insights. Implementing these recommendations will not only enhance operational efficiency but also secure a robust market position in the perpetually evolving landscape of intranasal drug and vaccine delivery.

Consolidated Summary and Forward-Looking Conclusion

In conclusion, the evolving landscape of intranasal drug and vaccine delivery offers a promising vista of opportunities and innovations that are redefining modern therapeutic practices. The convergence of transformational shifts, sophisticated segmentation insights, regional growth narratives, and competitive dynamics underscores a market that is both robust and responsive. As the industry continues to integrate novel technologies and embrace emergent research, stakeholders are witnessing unprecedented growth in clinical potential and patient accessibility.

This comprehensive analysis has outlined the critical trends that are shaping the future of intranasal delivery. A meticulous examination of segmentation based on drug type, formulation, devices, dosage, application, and end-user scenarios highlights the intricacy of the market and the diverse array of factors influencing its trajectory. Additionally, in-depth regional insights-from the well-established healthcare systems in the Americas and Europe, Middle East & Africa to the rapidly expanding opportunities in the Asia-Pacific-illustrate varying yet complementary growth dynamics.

Furthermore, an analysis of leading companies in the domain reveals strategic innovations that are central to driving market success. The interplay between cutting-edge research and real-world application is the cornerstone of market momentum, fortifying a base that is prepared to meet future challenges while capitalizing on emerging opportunities. Overall, this thorough evaluation confirms that the intranasal delivery market is not only poised for accelerated growth but also well-equipped to redefine the parameters of therapeutic innovation in the coming years.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising disease prevalence and syringe infection concerns propel growth in intranasal delivery systems
      • 5.1.1.2. Increasing popularity of self-administration of medications and non-invasive drug delivery routes
      • 5.1.1.3. Growing research and development activities focusing on innovations in intranasal vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative drug delivery methods and potential risk of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements related to intranasal drug delivery systems
      • 5.1.3.2. Substantial investments for R&D intranasal drug and vaccines delivery innovations
    • 5.1.4. Challenges
      • 5.1.4.1. Potential adverse reactions and side effects associated with intranasal drug administration
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing usage of non-opioid analgesics for chronic pain and long-term use owing to the lower risk of addiction and side effects
    • 5.2.2. Formulation Type: Innovative solutions and emerging applications in intranasal drug & vaccine delivery
    • 5.2.3. Device Type: Rising demand for atomizers owing to precision and efficacy in emergency treatments
    • 5.2.4. Dosage: Growing preference for multi-dose formats in large-scale immunization programs and chronic treatment protocols owing to cost-effectiveness and material efficiency
    • 5.2.5. Application: Rising preference for intranasal drug & vaccine delivery in allergy treatment to administer corticosteroids and antihistamines
    • 5.2.6. End-User: Expanding utilization of intranasal drug & vaccine delivery in homecare setups owing to better convenience and privacy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intranasal Drug & Vaccine Delivery Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Analgesics
    • 6.2.1. Non-opioids
    • 6.2.2. Opioids
  • 6.3. Antihistamines
  • 6.4. Steroids
  • 6.5. Vaccines
    • 6.5.1. Inactivated Vaccines
    • 6.5.2. Live Attenuated Vaccines
    • 6.5.3. mRNA-based Vaccine

7. Intranasal Drug & Vaccine Delivery Market, by Formulation Type

  • 7.1. Introduction
  • 7.2. Gel Formulations
  • 7.3. Liquid Formulations
  • 7.4. Powder Formulations

8. Intranasal Drug & Vaccine Delivery Market, by Device Type

  • 8.1. Introduction
  • 8.2. Atomizer
  • 8.3. Nasal Dropper
  • 8.4. Nasal Spray

9. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 9.1. Introduction
  • 9.2. Multi-dose
  • 9.3. Unit-dose

10. Intranasal Drug & Vaccine Delivery Market, by Application

  • 10.1. Introduction
  • 10.2. Allergy Treatment
  • 10.3. Hormone Replacement
  • 10.4. Neurological Conditions
  • 10.5. Pain Management
  • 10.6. Psychiatric Disorders
  • 10.7. Therapeutic Drug Delivery

11. Intranasal Drug & Vaccine Delivery Market, by End-User

  • 11.1. Introduction
  • 11.2. Homecare
  • 11.3. Hospitals & Clinics
  • 11.4. Research & Academic Institution

12. Americas Intranasal Drug & Vaccine Delivery Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Intranasal Drug & Vaccine Delivery Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Orexo and Abera collaborate to advance intranasal powder vaccine development
    • 15.3.2. AuraVax Therapeutics secures a research contract from BARDA to investigate NanoSTING platform
    • 15.3.3. Aptar Pharma's strategic acquisition of SipNose enhances innovation in intranasal drug delivery systems
    • 15.3.4. FDA approval for at-home FluMist nasal spray offers needle-free solution to boost flu vaccination rates
    • 15.3.5. Rokote Laboratories partners with 3PBIOVIAN to advance intranasal COVID-19 vaccine manufacturing for clinical trials
    • 15.3.6. CastleVax secures USD 34 million funding to propel innovative intranasal COVID-19 vaccine into advanced trials
    • 15.3.7. BARDA invests USD 500 million in next-generation intranasal and oral COVID-19 vaccines
    • 15.3.8. Merck Animal Health transforms intranasal vaccination with innovative CleanVax nozzles and shields for enhanced hygiene and comfort
    • 15.3.9. Strategic collaboration to innovate nasal drug delivery with soft mist technology
    • 15.3.10. Kindeva expands intranasal drug-delivery capabilities with Summit Biosciences acquisition
    • 15.3.11. Oragenics acquisitions advance intranasal drug delivery for neurological treatments and market expansion
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. AstraZeneca PLC
    • 15.4.2. Pfizer Inc.
    • 15.4.3. Indivior PLC
    • 15.4.4. AptarGroup, Inc.

Companies Mentioned

  • 1. Altimmune, Inc.
  • 2. AptarGroup, Inc.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. Bayer AG
  • 6. Becton, Dickinson, and Company
  • 7. Bharat Biotech Ltd.
  • 8. Boehringer Ingelheim International GmbH.
  • 9. Catalent, Inc
  • 10. DCA Design International Limited
  • 11. Emergent BioSolutions Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Hovione Limited
  • 14. Impel Pharmaceuticals LLC.
  • 15. Indivior PLC
  • 16. Intersect ENT by Medtronic plc
  • 17. Intertek Group PLC
  • 18. Johnson & Johnson Services, Inc.
  • 19. Kindeva Drug Delivery L.P.
  • 20. Merck & Co., Inc.
  • 21. Neurelis, Inc.
  • 22. Novartis AG
  • 23. OptiNose, Inc.
  • 24. Pfizer Inc.
  • 25. Recipharm AB.
  • 26. Sanofi S.A.
  • 27. Teleflex Incorporated
  • 28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-CURRENCY
  • FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET MULTI-LANGUAGE
  • FIGURE 3. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
  • FIGURE 4. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA INTRANASAL D